Metropolis Healthcare announced robust financial performance for the second quarter of FY27, with revenue climbing 16% YoY to ₹497 crore and Profit After Tax (PAT) surging 43% YoY to ₹75 crore. The company also reported a 24% increase in EBITDA. Key growth drivers included increased patient and test volumes, expansion in B2C and B2B segments, and a growing presence in Tier III cities.
Metropolis Healthcare Announces Strong Q2 FY27 Financials
Metropolis Healthcare has reported a strong performance for the second quarter ended September 30, 2026 (Q2 FY27). The company announced a 16% year-over-year increase in revenue, reaching ₹497 crore, and a significant 43% rise in Profit After Tax (PAT) to ₹75 crore. This performance reflects the growing demand for diagnostic services and effective business strategies implemented by the company.
Key Financial Highlights
The unaudited consolidated financial results for Q2 FY27 showcase notable improvements across key financial metrics:
- Revenue from Operations: ₹496.8 crore (Q2 FY27) vs ₹429.2 crore (Q2 FY26) – a 15.8% increase.
- Reported EBITDA: ₹134.9 crore (Q2 FY27) vs ₹108.9 crore (Q2 FY26) – a 23.9% increase. EBITDA Margin improved by 180 basis points to 27.2%.
- Profit After Tax (PAT): ₹75.5 crore (Q2 FY27) vs ₹52.9 crore (Q2 FY26) – a 42.7% increase. PAT Margin improved by 290 basis points to 15.2%.
- H1 FY27 Performance: Revenue grew 16.2% YoY to ₹947.0 crore, and PAT increased 34.9% YoY to ₹132.4 crore.
Operational and Segmental Growth Drivers
The company highlighted several operational achievements contributing to its growth:
- Patient and Test Volumes: Patient volume grew 10% YoY to 4.1 million, and test volume increased 11% YoY to 8.7 million.
- B2C Revenue: Increased by 17% YoY to ₹289 crore, driven by customer engagement and marketing initiatives.
- B2B Revenue: Rose by 15% YoY to ₹208 crore, attributed to new client acquisitions and increased specialized test uptake.
- TruHealth Revenue: Grew 20% YoY to ₹86 crore, reflecting a preference for premiumization and preventive care.
- Specialty Revenue: Saw a 20% YoY increase to ₹198 crore, boosted by advanced genomic and cancer testing.
- Revenue per Patient (RPP): Increased by 6% YoY to ₹1,221.
- Revenue per Test (RPT): Improved by 5% YoY to ₹572.
- Geographical Expansion: Tier III cities emerged as the fastest-growing markets, with revenue rising approximately 20% YoY. Metropolis now has a presence in around 750 towns.
Dividend Declaration
The Board of Directors has declared an interim dividend of ₹1 per share.
Management Commentary
Ms. Ameera Shah, Promoter and Executive Chairperson, expressed satisfaction with the performance, stating, “We are pleased with our H1FY27 performance, with revenue up 16% and no price increase, reflecting the trust of patients and clinicians.” She emphasized the company’s focus on building a differentiated and future-ready platform in diagnostics.
Mr. Surendran Chemmenkotil, Managing Director, added, “Q2FY27 was a strong quarter, with EBITDA up 24% and margin expanding 180 basis points to 27.2%, reflecting steadily improving operating performance.” He outlined plans to extend presence in Tier II and III towns, scale the wellness and specialty portfolio, and broaden engagement with doctors and hospitals.
Source: BSE
